Background: The exact mechanisms for antipsychotic-induced extrapyramidal side-effects have remained obscure despite intensive research. Previous studies have highlighted a central role for nigral dopamine D(2) receptors in the control of motor functions.
Aims: The aim of the present study was to examine relationships between dopamine D(2) receptor binding in both substantia nigra and temporal cortex with extrapyramidal symptoms among antipsychotic-treated patients with schizophrenia.
Methods: Single-photon emission-computed tomography (SPECT) ligand [(123)I]epidepride was used to determine dopamine D(2/3) apparent binding potential in 13 antipsychotic-treated (seven with clozapine, four with olanzapine and two with haloperidol) patients with schizophrenia. Extrapyramidal symptoms were assessed with the Simpson and Angus Scale (SAS).
Results: A statistically significant correlation was observed between dopamine D(2/3) receptor apparent binding potential in the substantia nigra and extrapyramidal side-effects (r = -0.62, P = 0.024). No correlations were detected in the temporal cortex between dopamine D(2/3) receptor binding and extrapyramidal side-effects.
Conclusions: These findings support the role of dopamine D(2) autoreceptors in substantia nigra regarding drug-induced movement disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08039480903484076 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impaired Sequential Working Memory in Patients With Young Onset Parkinson's Disease.
Brain Behav
December 2024
Institute of Neuroscience, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
Background: Sequential working memory refers to the cognitive ability to maintain and/or manipulate a set of ordered representations within a short period. It remains unclear whether sequential working memory is impaired in patients with young onset Parkinson's disease (YOPD).
Objectives: The aim of this study is to evaluate the sequential working memory in patients with YOPD.
Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres.
Neuro Oncol
October 2024
Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background: Glioblastoma (GBM), a primary malignant brain tumor, has a poor prognosis, even with standard treatments such as radiotherapy and chemotherapy. In this study, we explored the anticancer effects of the synergistic combination of perphenazine (PER), a dopamine receptor D2/3 (DRD2/3) antagonist, and temozolomide (TMZ), a standard treatment for GBM, in patient-derived human GBM tumorspheres (TSs).
Methods: The biological effects of the combination of PER and TMZ in GBM TSs were assessed by measuring cell viability, ATP, stemness, invasiveness, and apoptosis.
A dopaminergic basis of behavioral control.
bioRxiv
October 2024
Helen Wills Neuroscience Institute, University of California, Berkeley.
Both goal-directed and automatic processes shape human behavior, but these processes often conflict. is the decision about which process guides behavior. Despite the importance of behavioral control for adaptive decision-making, its neural mechanisms remain unclear.
View Article and Find Full Text PDFDopamine D2 receptor activation counteracts olfactory dysfunction and related cellular abnormalities in experimental parkinsonism.
Heliyon
August 2024
Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.
Olfactory dysfunction is a common non-motor symptom associated with Parkinson's disease (PD). This condition usually appears before the onset of the cardinal motor symptoms and is still poorly understood. Here, we generated a mouse model of early-stage PD based on partial 6-hydroxydopamine (6-OHDA) lesion of the dorsal striatum to reproduce the olfactory deficit and associated cellular and electrophysiological anomalies observed in patients.
View Article and Find Full Text PDFAmphetamine-Induced Dopamine Release Predicts 1-Year Outcome in First-Episode Psychosis: A Naturalistic Observation.
Schizophr Bull
December 2024
Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- There’s a theory that suggests schizophrenia symptoms might get better with medicine that blocks certain dopamine receptors, but not everyone gets better.
- Researchers studied 21 people who were just diagnosed with schizophrenia and hadn’t taken medication before to see how dopamine release affected their symptoms over a year.
- They found that certain areas of the brain releasing more dopamine were linked to improvements in symptoms, helping to understand why some patients respond better to treatment than others.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!